Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy

Background: Whether to continue oral anticoagulant therapy beyond 6 months after an “unprovoked” venous thromboembolism is controversial. We sought to determine clinical predictors to identify patients who are at low risk of recurrent venous thromboembolism who could safely discontinue oral anticoagulants. Methods: In a multicentre prospective cohort study, 646 participants with a first, unprovoked major venous thromboembolism were enrolled over a 4-year period. Of these, 600 participants completed a mean 18-month follow-up in September 2006. We collected data for 69 potential predictors of recurrent venous thromboembolism while patients were taking oral anticoagulation therapy (5–7 months after initiation). During follow-up after discontinuing oral anticoagulation therapy, all episodes of suspected recurrent venous thromboembolism were independently adjudicated. We performed a multivariable analysis of predictor variables (p < 0.10) with high interobserver reliability to derive a clinical decision rule. Results: We identified 91 confirmed episodes of recurrent venous thromboembolism during follow-up after discontinuing oral anticoagulation therapy (annual risk 9.3%, 95% CI 7.7%–11.3%). Men had a 13.7% (95% CI 10.8%–17.0%) annual risk. There was no combination of clinical predictors that satisfied our criteria for identifying a low-risk subgroup of men. Fifty-two percent of women had 0 or 1 of the following characteristics: hyperpigmentation, edema or redness of either leg; D-dimer ≥ 250 μg/L while taking warfarin; body mass index ≥ 30 kg/m2; or age ≥ 65 years. These women had an annual risk of 1.6% (95% CI 0.3%–4.6%). Women who had 2 or more of these findings had an annual risk of 14.1% (95% CI 10.9%–17.3%). Interpretation: Women with 0 or 1 risk factor may safely discontinue oral anticoagulant therapy after 6 months of therapy following a first unprovoked venous thromboembolism. This criterion does not apply to men. (http://Clinicaltrials.gov trial register number NCT00261014)

[1]  S. Kahn,et al.  Inter-observer reliability of measures to assess the post-thrombotic syndrome , 2007, Thrombosis and Haemostasis.

[2]  G. Agnelli,et al.  Treatment of DVT: how long is enough and how do you predict recurrence , 2008, Journal of Thrombosis and Thrombolysis.

[3]  J. Żyłkowska [Optimal time to introduce secondary prophylactic anticoagulation therapy after an episode of obstructive lung disease or venous thrombosis - will it be defined by testing of D-dimer?]. , 2007, Kardiologia polska.

[4]  Paolo Prandoni,et al.  The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. , 2007, Haematologica.

[5]  A. Iorio,et al.  D-dimer testing to determine the duration of anticoagulation therapy. , 2006, The New England journal of medicine.

[6]  S. Schulman,et al.  Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis , 2006, The Lancet.

[7]  O. Linder,et al.  Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months , 2006, Journal of thrombosis and haemostasis : JTH.

[8]  E. Minar,et al.  The post‐thrombotic syndrome: risk factors and impact on the course of thrombotic disease , 2005, Journal of thrombosis and haemostasis : JTH.

[9]  B. Cosmi,et al.  The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients. , 2005, Haematologica.

[10]  Giancarlo Agnelli,et al.  Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[11]  James Douketis,et al.  Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism , 2003, Annals of Internal Medicine.

[12]  Jonathan Dreyer,et al.  Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. , 2003, The New England journal of medicine.

[13]  P. Wells,et al.  The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism , 2003, Thrombosis and Haemostasis.

[14]  O. Wagner,et al.  D-dimer levels and risk of recurrent venous thromboembolism. , 2003, JAMA.

[15]  T. Baglin,et al.  Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study , 2003, The Lancet.

[16]  M. Gent,et al.  Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[17]  W. Ageno,et al.  Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism , 2003, Annals of Internal Medicine.

[18]  P. Ridker,et al.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[19]  M. Prins,et al.  Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism , 2002, Annals of Internal Medicine.

[20]  P. Prandoni,et al.  Three months vs. one year of oral anticoagulant therapy for idiopathic deep venous thrombosis , 2002 .

[21]  B. Cosmi,et al.  Risk of Venous Thromboembolism Recurrence: High Negative Predictive Value of D-dimer Performed after Oral Anticoagulation Is Stopped , 2002, Thrombosis and Haemostasis.

[22]  L. Galli,et al.  Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. , 2002, Haematologica.

[23]  W. Ageno,et al.  Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. , 2001, The New England journal of medicine.

[24]  I. Durieu,et al.  Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis , 2001, Circulation.

[25]  M Stain,et al.  High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. , 2000, The New England journal of medicine.

[26]  L. Melton,et al.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. , 2000, Archives of internal medicine.

[27]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[28]  L. Melton,et al.  Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. , 1999, Archives of internal medicine.

[29]  J. Douketis,et al.  Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. , 1998, JAMA.

[30]  M. Prins,et al.  Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. , 1997, The New England journal of medicine.

[31]  A. Laupacis,et al.  Clinical prediction rules. A review and suggested modifications of methodological standards. , 1997, JAMA.

[32]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[33]  P. de Moerloose,et al.  VIDAS D-dimer: fast quantitative ELISA for measuring D-dimer in plasma. , 1996, Clinical chemistry.

[34]  J Pekkanen,et al.  Reliability of near-infrared interactance body fat assessment relative to standard anthropometric techniques. , 1995, Journal of clinical epidemiology.

[35]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[36]  K. Schulman,et al.  Cost-effectiveness analyses. , 1995, The New England journal of medicine.

[37]  S. Schulman,et al.  A Comparison of Six Weeks With Six Months of Oral Anticoagulant Therapy After a First Episode of Venous Thromboembolism , 1996 .

[38]  Research Committee on Type 1 Diabetes of the Japan Diabetes Society Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism , 1992, The Lancet.

[39]  R. Hull,et al.  Antithrombotic therapy for venous thromboembolic disease. , 1986, Chest.

[40]  H. Sox,et al.  Clinical prediction rules. Applications and methodological standards. , 1985, The New England journal of medicine.